Abstract
Purpose To determine if pelvic/ovarian and omental lesions of ovarian cancer can be reliably segmented on computed tomography (CT) using fully automated deep learning-based methods.
Materials and Methods A deep learning model for the two most common disease sites of high grade serous ovarian cancer lesions (pelvis/ovaries and omentum) was developed and compared against the well-established “no-new-Net” (nnU-Net) framework and unrevised trainee radiologist segmentations. A total of 451 pre-treatment and post neoadjuvant chemotherapy (NACT) CT scans collected from four different institutions were used for training (n=276), hyper-parameter tuning (n=104) and testing (n=71) of the methods. The performance was evaluated using the Dice similarity coefficient (DSC) and compared using a Wilcoxon test on paired results
Results Our model outperforms the nnU-Net framework by a significant margin for both disease (validation: p=1×10-4,1.5×10-6, test: p=0.004, 0.005) and it does not perform significantly different from a trainee radiologist for the pelvic/ovarian lesions (p=0.392). On an independent test set (n=71), the model achieves a performance of 72±19 mean DSC for the pelvic/ovarian and 64±24 for the omental lesions.
Conclusion Automated ovarian cancer segmentation on CT using deep neural networks is feasible and achieves performance close to a trainee-level radiologist for pelvic/ovarian lesions.
Summary Deep learning-based models were used to assess whether fully automated segmentation is feasible for the main two disease sites in high grade serous ovarian cancer.
Key Points
First automated approach for pelvic/ovarian and omental ovarian cancer lesion segmentation on CT images.
Automated segmentation of ovarian cancer lesions can be comparable with manual segmentation of trainee radiologists with three years of experience in oncological and gynecological imaging.
Careful hyper-parameter tuning can provide models significantly outperforming strong state-of-the-art baselines.
Competing Interest Statement
ES is co-founder and shareholder of Lucida Medical Ltd. LR has received consulting fees from Lucida Medical Ltd.
Funding Statement
This work was partially supported by The Mark Foundation for Cancer Research and Cancer Research UK Cambridge Centre [C9685/A25177], the Wellcome Trust Innovator Award [RG98755] and the CRUK National Cancer Imaging Translational Accelerator (NCITA) [C42780/A27066]. Additional support was also provided by the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. This project has been funded in whole or in part with Federal funds from the National Cancer institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91019D00024. CBS acknowledges support from the Leverhulme Trust project on "Breaking the non-convexity barrier", the Philip Leverhulme Prize, the Royal Society Wolfson Fellowship, the EPSRC grants EP/S026045/1 and EP/T003553/1, EP/N014588/1, EP/T017961/1, European Union Horizon 2020 research and innovation programmes under the Marie Skodowska-Curie grant agreement No. 777826 NoMADS and No. 691070 CHiPS, the Cantab Capital Institute for the Mathematics of Information and the Alan Turing Institute. The work by Oektem was supported by the Swedish Foundation of Strategic Research under Grants AM13-0049.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients within the main data set were treated at Cambridge University Hospitals NHS Foundation Trust between 2009 and 2020 and were recruited into a prospective clinical study. Approval to this study was given by the Cambridgeshire Research Ethics Committee (REC reference numbers: 08/H0306/61). All patients within the Barts data set were treated at Barts Health NHS Trust between 2009 and 2018 and recruited into prospective clinical study. Approval to this study was given by the Clinical Ethics Committee at Barts and the NHS Trust (IRAS reference numbers: 243824). Imaging data used for this study was collected under the Gynecologic Cancer Center of Excellence Program Tissue and Data Acquisition Network less than minimal risk Protocol #20110222 under the Western Copernicus Group (WCG) Institutional Review Board (IRB), representing the Inova Health System IRB (Protocol 15-1813) and the Duke University Health System IRB (Protocol Pro00013703), or Protocol 2004CO0124 under the Ohio State University IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All CT scans and segmentations used for training, validation and testing of the methods are not publicly available, except for the 20 scans obtained from the Cancer Imaging Archive. The trained models are publicly available.
Abbreviations
- 3D
- three-dimensional
- CT
- Computed Tomography
- DSC
- Dice similarity coefficient
- HGSOC
- high grade serous ovarian carcinoma
- IPS
- immediate primary surgery
- NACT
- neoadjuvant chemotherapy
- nnU-Net
- no-new-Net
